Elite Pharmaceuticals, Inc.
ELTP
Get informed when a big investor buys or sells
+ FollowMarket Cap$312.39M
Close$
$0.26
8.5% downside
Current Fair Value
8.5% downsideOvervalued by 8.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $312.39 Million |
|---|---|
| Enterprise Value | $276.10 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.04 |
| Beta | 0.4 |
| Outstanding Shares | 1,077,236,000 |
Return
| Return on Equity | 54.06% |
|---|---|
| Return on Assets | 40.57% |
| Return on Invested Capital | 36.48% |
Valuation & Multiples
| P/E Ratio | 5.8 |
|---|---|
| PEG | -2.89 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.96 |
| Enterprise Value to EBIT | 6.93 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%0% |
|---|---|
| Total Invested | $180▼ 26.53% |
| Investors Holding | 10% |
ESG Score
No data